Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin.
Cisplatin, but not its trans geometric isomer, is a potent anticancer drug whose biological activity is a consequence of the formation of covalent adducts between the platinum compound and certain bases in DNA. Two classes of proteins have recently been identified that bind preferentially to damaged sites: proteins that specifically recognize those sites as a first step in their repair, and those that bind to such sites by virtue of structural similarity between the modified DNA and their own natural binding sites. Both classes of proteins may be involved, perhaps in opposing ways, in the cytotoxic effect of the drug.
Zlatanova
J
J
Department of Biochemistry and Biophysics, Oregon State University, Corvallis 97331-7305, USA.
Yaneva
J
J
Leuba
S H
SH
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001665:Binding Sites; D002945:Cisplatin / Q000494:pharmacology*; D004247:DNA / Q000187:drug effects*; D018736:DNA Adducts; D004249:DNA Damage; D011088:DNA Ligases / Q000378:metabolism*; D004260:DNA Repair / Q000187:drug effects; D004261:DNA Replication / Q000187:drug effects; D006609:High Mobility Group Proteins / Q000378:metabolism; D006801:Humans
D000970:Antineoplastic Agents; D018736:DNA Adducts; D006609:High Mobility Group Proteins; C057270:cisplatin-DNA adduct; C034697:transplatin; D004247:DNA; D011088:DNA Ligases; D002945:Cisplatin